The role of hydrogen sulfide in doxorubicin-induced drug resistance in hepatocellular carcinoma cells by Stokes, Eric
  
 
The role of hydrogen sulfide in doxorubicin-induced drug resistance 
in hepatocellular carcinoma cells  
 
 
by 
 
Eric Stokes   
 
 
A thesis submitted in partial fulfillment 
of the requirements for the degree of 
Master of Science (MSc) in Biology 
 
 
 
The Faculty of Graduate Studies 
Laurentian University 
Sudbury, Ontario, Canada 
 
 
 
© Eric Stokes, 2018 
  
ii 
THESIS DEFENCE COMMITTEE/COMITÉ DE SOUTENANCE DE THÈSE 
Laurentian Université/Université Laurentienne 
Faculty of Graduate Studies/Faculté des études supérieures 
 
Title of Thesis     
Titre de la thèse   The role of hydrogen sulfide in doxorubicin-induced drug resistance in 
hepatocellular carcinoma cells 
 
Name of Candidate   
Nom du candidat    Stokes, Eric 
       
Degree                            
Diplôme                            Master of Science 
 
Department/Program    Date of Defence 
Département/Programme  MSc Biology  Date de la soutenance September 17, 2018 
                                                       
APPROVED/APPROUVÉ 
 
Thesis Examiners/Examinateurs de thèse: 
                                                      
Dr. Guangdon Yang  
(Supervisor/Directeur de thèse) 
 
Dr. Eric Gauthier    
(Committee member/Membre du comité)    
        
Dr. Jeffrey Gagnon      
(Committee member/Membre du comité)    
      Approved for the Faculty of Graduate Studies 
Dr. Rui Wang     Approuvé pour la Faculté des études supérieures 
(Committee member/Membre du comité)   Dr. David Lesbarrères 
      Monsieur David Lesbarrères 
Dr. Wenbin Liang      Dean, Faculty of Graduate Studies 
(External Examiner/Examinateur externe)   Doyen, Faculté des études supérieures 
 
 
                                                 
ACCESSIBILITY CLAUSE AND PERMISSION TO USE 
 
I, Eric Stokes, hereby grant to Laurentian University and/or its agents the non-exclusive license to archive and make 
accessible my thesis, dissertation, or project report in whole or in part in all forms of media, now or for the duration 
of my copyright ownership. I retain all other ownership rights to the copyright of the thesis, dissertation or project 
report. I also reserve the right to use in future works (such as articles or books) all or part of this thesis, dissertation, 
or project report. I further agree that permission for copying of this thesis in any manner, in whole or in part, for 
scholarly purposes may be granted by the professor or professors who supervised my thesis work or, in their 
absence, by the Head of the Department in which my thesis work was done. It is understood that any copying or 
publication or use of this thesis or parts thereof for financial gain shall not be allowed without my written 
permission. It is also understood that this copy is being made available in this form by the authority of the copyright 
owner solely for the purpose of private study and research and may not be copied or reproduced except as permitted 
by the copyright laws without written authority from the copyright owner. 
 
  iii
Abstract  
Doxorubicin is one of the most common chemical agents used in the treatment of cancers. 
Doxorubicin-treated cancer cells often develop drug resistance due to alterations in the 
trafficking and metabolism of the drug, which severely limits the drug’s effectiveness. This is 
seen at especially high rates in human hepatocellular carcinoma (HCC), the most common form 
of liver cancer. H2S is an important gasotransmitter and is involved in a variety of cellular 
functions and pathophysiologic processes. The role of H2S in drug resistance in cancer cells is 
still unclear. In this study, by using a human hepatocellular carcinoma cell line (HepG2), we 
found that NaHS (an H2S donor) was able to reduce cancer cell viability and colony formation in 
a doxorubicin dose dependent manner, while H2S alone did not show any effect. The expression 
of H2S-generating enzyme cystathionine gamma-lyase (CSE) but not cystathionine beta-synthase 
(CBS) was reduced by doxorubicin treatment. In addition, H2S promoted cellular retention of 
doxorubicin in HepG2 cells, possibly by suppressing the expression of ABCA1 and ABCG8, two 
drug efflux proteins. LXRα acts as a transcription factor for ABCA1 and ABCG8, however our 
findings showed that H2S had no effect on the protein expression and S-sulfhydration of LXRα, 
suggesting LXRα is not involved in H2S-regulated expressions of ABCA1 and ABCG8. In 
comparison with the parental cells, CSE expression was also reduced in doxorubicin-resistant 
cells. Exogenously applied NaHS reversed the drug resistance in doxorubicin-resistant cells. In 
conclusion, our study provides a novel solution for reversing drug resistance by targeting H2S 
signaling. 
Key words: H2S, Cystathionine gamma-lyase, human hepatocellular carcinoma, doxorubicin, 
drug resistance 
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Abbreviations: 
3MST: 3-mercaptopyruvate sulfurtransferase  
ABC: ATP-binding cassette  
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EDRF: Endothelial derived growth factor 
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HAIC: Hepatic artery-infusion chemotherapy 
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1. Introduction 
1.1 Gasotransmitters 
In 1980, Drs.Furchgott and Zawadzki described the ability of an unknown factor, released by 
endothelial cells, to induce the relaxation of smooth muscle cells. They termed this molecule an 
endothelial derived relaxing factor (EDRF), and in 1987, it was discovered to be the gas 
molecule nitrous oxide. (1). Their research was awarded the Nobel Prize in 1998 alongside Drs. 
Ignarro and Murad, sparking the interest in the potential for other endogenously produced 
gaseous molecules to have similar signalling properties. Since that time, both carbon monoxide 
(CO) and most recently, hydrogen sulfide (H2S) have been implicated as physiologically relevant 
molecules in mammalian physiology. In recognition of these gaseous signalling molecules, Dr. 
Wang coined and defined the term “gasotranmsmitters”. In order to be recognized as a member 
of the gasotransmitter group, a molecule needs to meet the 6 criteria outlined below (adapted 
from (2)); 
1. They are small molecules of gas. 
2. They are freely permeable to the cell membrane. As such, their intracellular and 
intercellular movements do not exclusively rely on cognate membrane receptors or transport 
proteins 
3. They are endogenously generated in mammalian cells with specific substrates and 
enzymes; more than the products of metabolism, their production is regulated to fulfill signaling 
messenger functions. 
4. They have well-defined, specific functions at physiologically relevant concentrations. 
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5. Functions of endogenous gases can be mimicked by their exogenously applied 
counterparts. 
6. They are involved in signal transduction and have specific cellular and molecular 
targets. 
1.2. H2S in mammalian physiology 
H2S has a molecular weight of 34.1 g/mol and is a flammable gas with no colour. It is 
most commonly associated with its distinct “rotten egg” smell. Initial H2S research focused 
mostly on it’s cytotoxic effects, as well as it’s potential as a major workplace safety concern in 
the oil industry (3). At the time of it’s discovery, endogenous H2S production in brain tissues was 
widely considered to be nothing more than metabolic waste (4). It wasn’t until the discovery of 
nitric oxide as an important signalling molecule researchers began to look at other endogenously 
produced gaseous molecules. Since then, the endogenous production of H2S has been well 
described, and is facilitated by three major enzymes: cystathionine -synthase (CBS), 
cystathionine -lyase (CSE), and 3-mercaptopyruvate sulfurtransferase (3MST) in conjugation 
with cysteine aminotransferase (CAT). These enzymes catalyze the conversion of L-cysteine to 
H2S with pyridoxal 5’ phosphate (vitamin B6) as a cofactor (Fig 1.). Given the importance of L-
cysteine in the production of H2S, the regulation of appropriate circulating cysteine is critical for 
maintaining H2S homeostasis. The production of cysteine in mammalian tissues is performed 
through the reverse transsulfuration pathway and uses the H2S generating enzymes CSE and 
CBS to convert homocysteine to cystathionine, and then finally to cysteine (Fig 1.). 
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Figure 1. Mammalian endogenous generation of H2S through reverse transsulfuration 
H2S is capable of inducing cellular changes through a process known as protein S-
sulfhydration. This involves the conversion of thiol –SH groups in the cysteine residues of target 
proteins, to hydropersulfide –SSH groups, changing both the structure and functionality of these 
proteins (5). In doing so, H2S is capable of carrying out a huge number of signalling roles in 
most of the major organ systems. H2S-mediated S-sulfhydration of the NF-B p65 subunit has 
been shown to increase NF-B transcriptional activity, thus providing increased protection from 
cellular apoptosis (6). In human endothelial and fibroblast cells, S-sulfhydration of the mitogen-
activated protein kinase (MEK1) results in activation of poly (ADP-ribose) polymerase 1 
(PARP1), an important enzyme associated with DNA repair mechanisms (7). In response to 
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injury in a mouse model, increased levels of S-sulfhydration of the ATP synthase alpha subunit 
was associated with increased ATP synthase activity. This suggests a role S-sulfhydration in 
regulating and maintaining necessary energy production during times of cellular stress (8). 
The first described role of H2S as a gasotransmitter was it’s signalling properties within 
the nervous system. In the central nervous system, H2S is capable of enhancing the post-synaptic 
potentials of excitatory neurotransmission through increasing the sensitivity of NMDA receptors 
to glutamate signalling (9). H2S has also been shown to enhance the production of GABA 
receptors, leading to inhibitory neurotransmission in the central nervous system (10). In the 
cardiovascular system, exogenous H2S has been shown to reduce both heart rate and contractility 
through the opening of KATP channels, causing subsequent potassium efflux and 
hyperpolarization of myocytes (11, 12). The effect of H2S on KATP channels has also been 
implicated in the regulation of vascular smooth muscles, inducing the relaxation of blood vessels 
and thus regulating systemic blood flow (13). Of all the organ systems, H2S production in the 
liver occurs at exceptionally high levels, ranging from 30-90% higher than in vascular tissues. 
Because of this, some researchers have suggested that the liver is one of the major sites of H2S 
production in the body, and thus makes it a key target organ for studying the signalling roles of 
H2S (14). Currently, the main role of H2S in the liver is associated with the regulation of hepatic 
circulation through targeting of KATP channels. In doing so, H2S has been shown to induce 
vasodilation of the hepatic artery, thus ensuring adequate hepatic clearance (15).  
1.3 H2S in pathophysiology  
Given the importance of H2S production in mammalian physiology, researchers have 
become interested in describing the role of H2S in new and unique cellular signaling 
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mechanisms, specifically in the onset and regulation of disease. Today, our understanding of H2S 
in pathophysiology continues to open up new possibilities for H2S as a clinically relevant tool. 
Within the immune system, evidence has suggested both a pro and anti-inflammatory role 
of H2S. Given the importance of inflammation in the onset of many pathological conditions, as 
well as the danger that unregulated inflammation itself can pose, the role of H2S in inflammatory 
signalling should not be understated. The pro-inflammatory effect of H2S has been shown in 
lipopolysaccharide (LPS)-induced inflammation in mouse models, where plasma H2S levels 
were significantly increased. Additionally, administration of the H2S donor sodium hydrosulfide 
(NaHS) increased histological signs of inflammatory damage in lung and liver tissues (16). 
Elevated H2S levels were also shown to be associated with induced systemic inflammation, while 
the use of the CSE inhibitor DL-propargylglycine (PAG) significantly reduced the inflammatory 
response, and NaHS treatment further aggravated it (17). Conversely, as an anti-inflammatory 
molecule, one study showed the ability for inhaled H2S to restrict LPS induced systemic 
inflammation, again highlighting the sometimes conflicting regulatory activity of H2S (18). H2S 
donor treatment was shown to restrict the ability for leukocyte attachment to mesenteric 
endothelium cells, a key step in the initiation of inflammation. Similarly, H2S treatment was 
shown to limit induced paw edema in animal models, while inhibition of H2S production had the 
opposite effect (19).  
Another important function of this gasotransmitter is its ability to regulate apoptosis. In a 
manner similar to inflammation, the specific role of H2S in apoptosis is conflicted. H2S has been 
shown to induce apoptosis of human aortic smooth muscle cells (HASMC) (20). Overexpression 
of the gene encoding CSE, a major H2S-generating enzyme in the vascular system, enhanced 
endogenous H2S production and induced significant levels of HASMC apoptosis. Furthermore, 
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CSE inhibition through the use of CSE-specific short interfering (si)-RNA exaggerated these 
effects, suggesting the importance of endogenously produced H2S in sensitizing these cells to 
pro-apoptotic signaling events. It was shown that exogenous H2S increased protein expression of 
p21Cip and decreased protein expression of cyclin D1, further pointing to its role as a pro-
apoptotic signaling molecule (20).  Building upon these initial findings, researchers next looked 
at the role of H2S in regulating apoptotic events in cancerous cell lines. Lee et. al. investigated 
the effects of H2S exposure on both breast (MCF7) and liver (HepG2) cancer cell lines (21). 
Through the use of the H2S donor NaHS, continuous H2S treatment over a 5-day period resulted 
in a significant decrease in cell viability. This was also shown to be specific to only cancer cell 
line variants, with the same treatment having no effect on corresponding wild-type cells. The 
researchers proposed that this apparent anti-cancer effect was caused by H2S-induced uncoupling 
of mitochondrial electron transport chain. As a result, these cells become more heavily reliant on 
glycolytic ATP production, with lactic acid produced as a by-product. Because of the high 
metabolic demands of cancerous cells relative to wild-type cells, these effects became 
exaggerated in the cancerous lines. The increased lactic acid production and therefore decreased 
intracellular pH led to damaging cytosolic conditions and ultimately, cancer cell death (21). 
Similar inhibitory effects were also seen in cancerous gastric cell lines. Following 24-hour H2S 
treatments at concentrations ranging from 200-800 M, gastric cancer (SGC7901) cells exhibited 
significant levels of apoptosis in a dose-dependent manner (22). In the same study, H2S was also 
shown to effectively inhibit both gastric cancer invasion and migration, reducing the ability of 
the cancerous cells to metastasise. It was proposed that the H2S-induced the up regulation of 
Bax, Cytochrome C and Caspase 3, important factors in the intrinsic apoptotic pathway, was 
responsible for these effects (22).  
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However, equally convincing data has been collected suggesting that instead of 
stimulating cell apoptosis, H2S actually increases cell proliferation and metabolic activity. Szabo 
et al. presented these findings, using a colon cancer cell line, HCT116 (23). Szabo and his 
colleagues found that CBS knockdown resulted in a significant decrease in H2S production, 
implicating CBS as the major H2S-generating enzyme in these cells. CBS-knockdown also 
resulted in an approximately 50% decrease in the levels of HCT 116 cell proliferation, while also 
resulting in down regulation of cellular respiration and ATP synthesis. Szabo et al. also treated 
both a non-cancerous colon cell line (NCM356) and the HCT 116 cells with aminooxyacetic acid 
(AOAA), a CBS inhibitor, and found that the resultant CBS inhibition had anti-proliferative 
effects in the HCT116, but not the NCM356 cells. Conversely, CBS overexpression in the 
NCM356 cells actually increased cell proliferation, highlighting how, even within the same 
tissue type, pathological cellular conditions can be affected by the signalling role of H2S. To 
explain these effects, the researchers pointed to the ability of H2S to promote cellular 
bioenergetic processes such as glycolytic and electron transport chain activity, as well as its 
stimulatory effects on cell survival mechanisms, such as the Akt-pathway (23). Other studies 
have pointed to the ability of H2S to scavenge reactive oxygen species (ROS) and to restrict 
tumor suppressing gene P53 expression to explain its stimulatory effects (24). A summary of 
some of the current knowledge on the inhibitory (Fig 2A) and stimulatory (Fig 2B) effects of 
H2S on cell growth and activity is provided below. 
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Figure 2. Inhibitory and proliferative signaling properties of H2S   
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While it is clear that H2S plays an important role in the regulation of inflammation and 
apoptosis, it does so to a wide degree of variability. As a result, it can exhibit sometimes 
opposing functions depending on factors such as the the type and concentration of H2S donor 
used, the modification of either endogenous or application of exogenous H2S sources, as well as 
the tissue type being studied. What is clear however, is the ability for H2S to play a key role in 
major disease processes. This offers the potential for new discoveries, especially in tissues where 
H2S production is significant, but its exact role is still poorly understood, the liver being a prime 
example of such conditions.  
1.4 H2S post-translational modifications of protein by S-sulfhydration 1    
S-sulfhydration, or S-persulfidation, is a newly discovered protein post-translational 
modification by yielding a hydropersulfide moiety (–SSH) in the active cysteine residues. By 
changing local conformation and the final activity of target proteins, S-sulfhydration is believed 
to mediate most of cellular responses initiated by H2S. Since the first finding of S-sulfhydration 
on proteins was described in 2009 (5), many proteins have been reported to be S-sulfhydrated 
and involved in the physiological and pathological functions of H2S. H2S acts as an endothelium-
deriving relaxing factor (EDRF) through S-sulfhydration of potassium channel proteins (25). S-
sulfhydration of Keap1 provides protection against cellular senescence via the regulation of Nrf2 
                                                 
 
1   (This section has been published as part of a review paper titled “H2S-mediated protein S-
sulfhydration: a prediction for its formation and regulation in Molecules. Vol. 2017, doi 
10.3390/molecules22081334). 
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activity (26). Recently, it was found that S-sulfhydration of MEK1 is associated with repairing 
damaged DNA inside the cell (7). eNOS S-sulfhydration regulates eNOS activity through the 
regulation of eNOS dimerization (27). In addition, abnormal protein S-sulfhydration have been 
found to be involved in multiple sclerosis (28), antioxidants (29), neuroprotection (30), and 
endoplasmic reticulum stress response (31) by altering enzymatic activity, protein localization, 
protein–protein interactions, and protein stability. 
Despite the importance of protein S-sulfhydration in diverse cellular functions and 
pathophysiological responses, the regulatory mechanism of protein S-sulfhydration are largely 
unclear. The interaction or competition between cysteine S-sulfhydration and other protein post-
translational modifications (Sulfenylation, S-nitrosylation, and glutathionylation, etc) in the same 
protein need to be determined. Due to the instability and transient nature of s-sulfhydration 
moieties, the development of better detection technology and methodologies for protein S-
sulfhydration is required for an improved understanding of its formation and wide biological 
implications. 
1.5 Primary hepatocellular carcinoma (HCC) 
      Primary HCC is the most common form of primary liver cancer, making up 70-85% of all 
liver cancer diagnoses. HCC has the second highest mortality rate of all cancers in men, and the 
sixth highest in women, making it one of the most significant cancer forms worldwide (32). 
While HCC variants exist, all of them are associated with deregulated hepatocyte cell growth, 
and in some cases, metastasis (33). HCC etiology in developing countries is most commonly 
associated with viral hepatitis B/C infection, while in western countries has been linked to 
alcoholism and obesity (32).  
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    The prognosis associated with HCC is quite poor and the overall survival rate of patients 
with HCC remains very low. The most successful treatment option available for individuals is 
complete liver transplantation, with a 5-year survival rate of 61%. Similarly, surgical removal of 
cancerous tissues has also shown to be an effective treatment strategy, with 5-year survival rates 
upwards of 50%. Despite their promise, these treatments are severely restricted by long wait 
periods, and the numerous co-morbidities associated with HCC complicate the procedures, 
including diabetes, kidney, and cardiovascular diseases (34). Other treatment forms include 
chemotherapeutic and radiotherapy, as well as selective blockage of blood supply to the tumor. 
These treatments are, again, limited in their usefulness based on the size and location of the 
tumor (35).  
    Chemotherapeutics are some of the most widely used treatment tools for most forms of 
cancer, including HCC. These chemicals are applied both systemically in a non tumor-specific 
manner, or locally targeted to the cancerous tissues. While the hepatic artery supplies the liver 
with 25% of total blood flow, the remainder coming from the portal vein, studies have shown 
that HCC tumors receive close to 90% of its blood supply from the hepatic artery (36). As such, 
treatments can be facilitated to supply chemotherapeutic agents directly to target HCC tissues 
through the hepatic artery, in a method known as hepatic artery-infusion chemotherapy (HAIC) 
(36, 37). Modern chemotherapeutics can be organized into the following classes as described in 
table 1.  
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Table 1. Classes of chemotherapeutic agents based on mode of activity (adapted from (38)). 
Class Example Applications 
 
Antimetabolites 5-fluorouracil   Hepatic artery infusion 
chemotherapy, HCC 
treatment 
Biological Agents  Bevacizumab  Colorectal metastases 
associated with HCC 
Multi-kinase Inhibitors Sorafenib  Systemic treatment of HCC 
and renal cell carcinoma 
(RCC) 
Platinum salts Cisplatin HCC and associated 
metastases treatment 
Antineoplastic Antibiotics Doxorubicin HCC and associated 
metastases treatment 
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Antimetabolites such as 5-fluorouracil work to inhibit the production of essential 
biomolecules such as nucleotides. Biological agents instead use the patients own immune system 
to directly target tumors or modulate hormone levels necessary for tumor establishment and 
growth, and are specifically useful in the treatment of breast and prostate cancers.  Agents such 
as sorafenib, which fall under the multi-kinase inhibitor class, target the signal transduction 
pathways associated with protein kinases. Sorafenib specifically blocks the protein kinase 
receptor for vascular endothelial growth factor (VEGF), which in turn prevents the production of 
new tumor vasculature, depriving the tumor of oxygen and inducing cell death. Platinum salts 
work through inducing DNA strand cross linkages which interrupts the DNA replication/ repair 
machinery, leading to apoptosis in the rapidly dividing cancer cells. One of the most well studied 
and widely used group of chemotherapeutics are the anti-neoplastic antibiotics. First discovered 
in the Streptomyces bacteria as a tool used to inhibit the growth of competitive bacteria, anti-
neoplastic antibiotics have clinical usefulness as well (38). Of the antineoplastic antibiotics 
available, doxorubicin is one of the most well studied and widely used agents, with clinical 
applications across a wide range of cancers, including HCC (39). 
1.6 Doxorubicin as a model chemotherapeutic agent 
    Doxorubicin, trade name as adriamycin, was first employed as an anticancer agent in 1970. 
Since that time, doxorubicin has become one of the most commonly used treatment tools for the 
management of cancers of the lung, breast, and liver to name a few (40–42). Doxorubicin carries 
out it’s cytotoxic effects as outline in figure 3. 
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(43) 
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  Doxorubicin is capable of directly inducing lipid peroxidation, thus damaging elements of 
the cell membrane and nucleus. While these effects have been shown to be especially damaging 
in cardiomyocytes, resulting in cardiotoxicity, it is not the primary mechanism in which 
doxorubicin induces cell death (44). The majority of doxorubicin’s effects come from 
interruption of DNA replication machinery and generation of ROS. Once inside the cell, 
doxorubicin is capable of interacting with mitochondrial reductases to produce a doxorubicin 
semiquinone, which then reduces free oxygen to a superoxide anion. The superoxide anion is 
then capable of further reacting with DNA, lipids, and proteins, damaging their functionality and 
inducing cell death (45). Doxorubicin itself can directly enter the nucleus and intercalate with 
DNA, inducing strand breaks. It can then bind topoisomerase II during the DNA repair process, 
sequestering it and reducing topoisomerase availability, thus leading to extensive, irreparable 
DNA damage, and thus cell death (46). While these effects will occur in both the patients healthy 
and cancerous cells, the direct targeting of DNA replication and repair machinery makes 
doxorubicin’s cytotoxicity more specific to cancer cells. While it’s clear that the anti-cancer 
effects of doxorubicin are significant and varied, like the other treatment methods mentioned 
above, it suffers from several limitations as well. One of the most significant and commonly seen 
in the treatment of HCC, is a reduced anti-cancer response over extended treatment periods, a 
condition known as multi-drug resistance (MDR). 
1.7 Multi-drug resistance (MDR) 
  Cellular resistance to normally toxic compounds was first studied in bacteria and by looking 
at the ability to adapt to certain antibiotic treatments (47). Building upon these findings, 
researchers discovered similar processes occurring in certain forms of human pathology, 
specifically in the treatment of cancers.  Given the many difficulties associated with the curative 
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treatment of HCC, patients often only have chemotherapeutic related treatments available to 
them (48). These treatments can last several months, following a reduction in the responsiveness 
to the chemotherapeutic agents, a phenomenon termed as multi-drug resistance (MDR) (49).  
      MDR is a multifactorial issue, and is characterized by changes in the metabolism, 
intracellular targeting, and transport of the chemotherapeutic agents (50). To study the onset and 
regulation of these mechanisms, researchers study protein expression levels associated with the 
cellular management of chemotherapeutics. The majority of research on MDR focuses on drug 
efflux, specifically through a group of membrane bound proteins called the ATP-binding cassette 
(ABC) transport proteins. There are 48 ABC transport proteins, which are divided into 7 
subgroups (A to G). These proteins are responsible for the transport of a wide variety of 
hydrophobic compounds such as metal ions, lipids, and sterol based metabolites, etc. (51). These 
ABC transporters facilitate unidirectional movement based on concentration gradients. The 
structure of most ABC transporters consists of 6 transmembrane -helices, in which the 
transmembrane pore is only accessible from one side of the lipid bilayer (52). The 
transmembrane domains act as the site of intracellular substrate binding, followed by the binding 
of ATP to the nucleotide binding domains. ATP hydrolysis catalyzes change of the transporter 
from the inward to outward facing conformation, followed by extracellular substrate release and 
ADP dissociation to return the protein back to the inward facing conformation, allowing for 
another round of transport activity (53). Abnormalities in ABC transporter protein expression 
and function can lead to a host of different disorders. Polymorphisms of ABCA2, expressed in 
brain tissues, has been associated with the changes in brain cholesterol transport associated with 
the onset of Alzheimer’s Disease (54), while ABCB4 mutations can result in a condition known 
as Progressive familial intrahepatic cholestasis (PFIC), characterized by bile accumulation in 
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hepatocytes (55). In cancerous cells, overexpression or increased activity levels of these proteins 
can result in decreased intracellular accumulation of chemotherapeutic agents, which has been 
implicated as one of the major causes MDR. The role of ABCB1/MDR1 in chemotherapeutic 
drug resistance has been extensively studied across several cell types ranging from myelogenous 
leukemia cells to breast cancer cells (56, 57). Other members of the ABC family have also been 
implicated in poor chemotherapeutic treatment prognosis. In human lung adenocarcinoma 
(A549) cells, ABCA1 down-regulation increased the cytotoxic activity of the chemotherapeutic 
agent nitidine (58). ABCG2/BCRP was shown to be highly expressed in a doxorubicin resistant 
human breast cancer (MCF-7/AdrVp) cell line, implicating it, and possibly other ABCG 
subgroup members, as major regulators of MDR. The regulation of these proteins is a tightly 
controlled process which includes a host of different transcription factors, some of which are 
shared between different members of the ABC group. Liver X receptors (LXRs) are a group of 
nuclear bound receptors that, through the binding of their ligands, promote the expression of 
target genes through the formation of a co-factor protein complex. The two subtypes of LXR’s, 
alpha and beta, are believed to be activated by the same ligands, and differ only in their tissue 
distribution, with alpha expression occurring mostly in the liver, and beta expression distributed 
evenly throughout most tissues (59). LXR’s are activated through the presence of sterol based 
metabolites and have been shown to regulate the expression of certain ABC proteins in order to 
control cholesterol transport. ABCA1 and ABCG8 are two ABC transport proteins that are 
induced by LXR alpha/beta to promote excess cholesterol efflux in gut lumen tissue (60). While 
the role of ABCA1 and ABCG8 in cholesterol homeostasis has been well described, their role in 
the efflux of chemotherapeutic agents has yet to be studied and could offer new insight into the 
development of MDR. 
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    The ability for cancerous cells to detoxify chemotherapeutic agents has also been shown to 
have importance in the onset of MDR (61) . The glutathione-S-transferase (GST) group is a large 
family of enzymes that are capable of catalyzing the conjugation of glutathione to various 
xenobiotic substrates for the purpose of detoxification (62). Once conjugated to glutathione, the 
xenobiotic substrates are then transported through the cytoplasm and processed through the 
mercapturic pathway in the cytosol. Once the resultant mercapturic acids are formed, they are 
released into circulation and then escape into the urine (63). GST is capable catalyzing the 
conjugation of glutathione to several different chemotherapeutic agents, removing them from 
circulation and the intended site of treatment, which is a proposed mechanism for MDR (62). 
Elevated GST levels have been studied as a prognostic tool for MDR in human ovarian cancer, 
with one study identifying 90% of drug resistant tumors as having increased GST levels (64). In 
Mouse embryo fibroblast cells, GST overexpression resulted in a protective effect against 
doxorubicin, but not other cytotoxic agents such as cisplatin, highlighting the selective role of the 
GST family in chemotherapeutic metabolism (65). It’s also important to recognize the ability for 
GST group members to regulate key cell survival pathways as well. One GST isoform, GSTP1-
1, is capable of inhibiting the activity of c-Jun N-terminal kinase (JNK), thus disrupting the 
mitogen-activated protein kinase (MAPK) pathway. In doing so GSTP1-1 prevents cellular 
apoptosis, and improves tumor cell survival (66).  It’s possible that through both its enzymatic 
and regulatory signaling activity, the GST family provides a dual mechanism for initiating MDR.  
    As discussed, one of the most studied and well described mechanisms associated with 
MDR is changes in the transport of chemotherapeutics. If these agents are not readily transported 
into the cytoplasm, or they are quickly removed, their ability to carry out their cytotoxic effects 
are severely restricted. While drug efflux has been shown to have the most significant effect on 
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MDR development, researchers are now looking at the role chemotherapeutic drug efflux might 
play in MDR. Most chemotherapeutic agents are transported into the cell through a group of 
influx transport proteins called the solute carriers (SLC) transport proteins. These proteins 
function through facilitated diffusion as both co-transporter and counter transporter proteins to 
allow for the cellular uptake of not only chemotherapeutic drugs, but many other important 
metabolites (67). SLC transporter dysfunction has been associated with certain disease 
conditions including inflammatory bowel disease and hyperbilirubinaemia (68). One specific 
member, SLC22A1, has been associated with doxorubicin influx across tissue types (69). 
Despite this, our understanding of their regulatory role in MDR requires further investigation.  
1.8 H2S as a putative regulator of MDR 
          Given the high incidence rate and serious impact that MDR in HCC has on patient 
survival, the need to study new signaling mechanisms associated with the onset of MDR in these 
tissues is critical (14). The potential for MDR-related H2S signaling can be highlighted by one 
study that found an increase in the response of ovarian cancer cells (A2780) to the 
chemotherapeutic agent cisplatin, through the silencing of the H2S-generating gene CBS (24). 
These findings were shown to extend to in vivo mouse models of ovarian cancer, where CBS-
directed siRNA coupled with cisplatin treatment had the most significant reduction in tumor size. 
In a similar manner, CSE and CBS inhibition increased the sensitivity of lung adenocarcinoma 
cells (A549) to another chemotherapeutic drug oxaliplatin (70). Other studies have noted 
increases in the levels of CSE and CBS in chemotherapeutic-resistance colon cancer cells 
(HCT116) compared to non-resistant cells (71). While these studies highlight the ability for H2S 
to induce MDR, the sometimes conflicting nature of H2S signaling presents the possibility for 
H2S to alternatively restrict MDR development, however this required further investigation. The 
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exceptionally high levels of H2S production shown in the liver suggests a key importance within 
these tissues. Given the high levels of liver H2S production, as well as the ability for H2S to 
regulate the response of cancer cells to various chemotherapeutics, the role of H2S in the 
regulation of MDR in HCC requires further investigation. Building upon these studies, this 
project looks to determine the possible involvement of H2S signaling in MDR in HCC and the 
underlying mechanisms. Through the use of human HCC (HepG2) cell lines and doxorubicin as 
a model chemotherapeutic agent, this study aims to investigate: 1), the interaction of doxorubicin 
and H2S on HepG2 cell viability and clonogenic formation; 2), the effect of doxorubicin on 
endogenous H2S signaling; 3), the regulation of ABC transporters, GST, and/or SLC in H2S-
altered MDR and the possible underlying mechanisms. In doing so, we hope to discover the 
potential role for H2S as a clinically relevant tool for the management of chemotherapeutic drug 
resistance in liver cancer.   
2. Methods 
2.1. Cell culture  
HepG2 cells were obtained from American Type Culture Collection (Manassas, VA) and 
cultured with Dulbecco's modified Eagle's medium (Sigma-Aldrich, Oakville, ON) supplemented 
with 10% fetal bovine serum, 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C in a 
humidified atmosphere of 5% CO2. The cells with 70-80% confluence were used for various 
treatments. 
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2.2. Establishment of a doxorubicin-resistant HepG2 cell line 
A doxorubicin-resistant HepG2 cell line was established by continuous exposure to low 
dose doxorubicin for a period of over 2 months. HepG2 cells were treated with an initial dose of 
50 nM doxorubicin for one month, followed by another month of 75 nM doxorubicin treatment. 
The medium was changed every 3 days. Doxorubicin-resistant HepG2 cells were determined 
based on morphological changes and a decreased sensitivity to doxorubicin treatment. 
Doxorubicin-resistant HepG2 cells were cultured in normal medium without doxorubicin for 1 
week prior to various treatments. 
 
2.3. Cell viability assay 
The effect of doxorubicin and NaHS treatment on the cell viability was measured with 
MTT assay as previously described (72). Briefly, 20,000-40,000 cell/well were seeded into a 96 
well plate in 200 l of medium for 24 hours at 37oC. Cells were then washed with 100 l PBS. 
After that, 200 l of medium containing either doxorubicin and/or NaHS were added for an 
additional 24-hour incubation. Following the treatment, cells were again washed with 100 l 
PBS, and 100 l of MTT (1 mg/ml) was added to each well. Following a 4-hour incubation at 
37oC, MTT was removed and 100 l of DMSO was added for 10 minutes. Absorbance at 570 
nM was read with a FLUOstar OPTIMA microplate spectrophotometer (BMG LABtech, 
Germany). Cell viability was expressed as a percentage of untreated control 
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2.4. Clonogenic assay 
To determine the effect of doxorubicin and H2S treatments on the colony forming 
abilities of HepG2 cells, a clonogenic assay was performed as previously described with some 
minor changes (73). HepG2 cells were first treated with/without doxorubicin (1 M) in the 
presence or absence of NaHS (30 M) for 24 hours. After that, the cells were washed with 2 mL 
PBS and trypsinized for cell counting. A total of 15,000 cells were plated into 35 mm dishes 
containing 2 mL regular medium. The cells were cultured at 37 oC for 2 weeks with medium 
changed every 3 days. Following fixation with acetic acid/methanol (1:7) and staining with 
crystal violet (0.5%), the pictures of the plates were taken and colony numbers were analyzed 
using Image J 1.43 software.  
 
2.5. Western blotting 
After different treatments, the cells were collected and lysed in the presence of protease 
inhibitors. The resultant extracts were centrifuged at 15,000 rpm for 15 minutes at 4oC for 
protein separation. Equal amounts of proteins (60 g) were mixed with loading buffer and placed 
at 95oC for 5 minutes, followed by separation with a 10% SDS-PAGE gel and transfer onto to 
nitrocellulose membranes (Pall Corporation, Pensacola, FL). The membranes were probed with 
appropriate primary antibodies and detected using peroxidase-conjugated secondary antibodies 
(Sigma-Aldrich, 1:5000) and visualized by ECL (GE Healthcare, Amersham, UK) (55). The 
following antibodies were diluted as follows with 3% milk in PBST: CSE 1/1000 (Protech, 
Rosemont, IL), CBS 1/100 (Santa Cruz, Dallas, TX), 3MST 1/1000 (Abnova, Walnut, CA), 
ABCA1 1/1000 (Abcam Toronto, ON), ABCB1 1/100 (Santa Cruz, Dallas, TX), ABCG8 1/100 
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(Santa Cruz, Dallas, TX), LXR 1/1000 (Abcam, Toronto, ON), LXR 1/1000 (Cell Signaling 
Tech., Danvers, MA), and -actin 1/5000 (Sigma-Aldrich). 
 
2.6. Real-time PCR 
Total RNA from the cells was collected using TriReagent (Sigma-Aldrich) and then 
reverse-transcribed into cDNA using random hexamer primers according to manufacturer’s 
protocol (Thermo Fisher Scientific, Ottawa, ON). Controls processed in the absence of reverse 
transcriptase were used to monitor contamination. The quantification of mRNA expression was 
performed with an iCycler iQ5 apparatus (Bio-Rad, Mississauga, ON) associated with the iCycler 
optical system software (version 3.1) using SYBR Green PCR Master Mix (Bio-Rad). The 
sequences of primers were: SLC22A16 (5’-CCTGGCGCCGTTCTCTGTGG-3’ and 5’-
CTGGGGGTAATCGTTCCGTTTTT-3’), GST (5’-AGGTTTTTGCCAATCCAGAAGAC-3’ 
and 5’-GTAGATCCGTGCTCCGACAAATA-3’), and                                                        
GAPDH (5’-GCGGGGCTCTCCAGAACATCAT-3’ and 5’-
CCAGCCCCAGCGTCAAAGGTG-3’). Relative mRNA quantification was calculated by using 
the arithmetic formula “2−ΔΔCT”, where ΔCT is the difference between the threshold cycle of a 
given target cDNA and an endogenous reference of GAPDH gene. 
 
2.7. Measurement of H2S production rate 
           H2S production rate, reflecting CSE activity, was measured with a methyl blue method as 
commonly described (74). Briefly, 10% w/v mouse liver tissue homogenates were mixed with 
100 mM potassium phosphate buffer, 10 mM L-cysteine, 2 mM pyridoxial 5’-phosphate, with or 
without 1 µM doxorubicin in the reaction flask. A center well containing 0.5 ml 1% zinc acetate 
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with a piece of filter paper (2 cm × 2.5 cm) was also put into the reaction flask. After being 
flushed with N2, the flask was kept at 37oC for 90 minutes. To stop the reaction, 0.5 ml of 50% 
trichloroacetic acid was added to the flasks. The flasks were then incubated at 37oC for 60 
minutes. After incubation, the contents of the center wells were then transferred to test tubes 
containing 3.5 ml H2O, and then 0.5 ml of 20 mM N,N-dimethyl-p-phenylenediamine sulfate in 
7.2 M HCl and 0.5 ml of 30 mM FeCl3 in 1.2 M HCl were added into the test tubes for 20 
minutes. The methylene blue generated from the reaction was quantified at 670 nm using a 
FLUOstar OPTIMA microplate spectrophotometer. The H2S produced from each reaction was 
determined with a standard curve of NaHS and expressed in nmole/g/min. 
 
2.8.  H2S direct interaction  
The direct interaction of doxorubicin with H2S was analyzed with a lead sulfur method to 
determine the ability for doxorubicin to sequester free H2S in solution (75). Briefly, 100 l of 
solution containing 30 M NaHS with or without 1 M doxorubicin was placed in a 96-well 
plate. Lead acetate paper was placed above the liquid phase contained in the 96-well plate with a 
cover. The reaction was incubated for 1 hour at 37oC in the dark. The well only containing NaHS 
acted as control. The lead acetate paper was then scanned and analyzed with Image J software. 
 
2.9. Doxorubicin efflux and influx assay 
          After HepG2 cells were treated with doxorubicin and/or NaHS for 24 hours, the cells were 
washed twice with PBS, and incubated with 2 mL PBS for additional 2 hours. Afterward, 1 mL 
sample of PBS was first taken from each plate for measurement of doxorubicin efflux. The cells 
were then collected for analysis of doxorubicin influx. The fluorescence of doxorubicin was read 
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at an excitation wavelength of 485 nm and an emission wavelength of 590 nm using a FLUOstar 
OPTIMA reader as previously described (76). The images of doxorubicin fluorescence were also 
taken using an inverted Olympus IX70 fluorescence microscope. 
 
2.10.  S-sulfhydration assay 
LXRα S-sulfhydration was performed as described previously (26, 77, 78).  Briefly, cells 
were sonicated in buffer containing 250 mM Hepes buffer (pH 7.7), 1 mM EDTA, 0.1 mM 
neocuproine and 100 µM deferoxamine following centrifuge at 13,000 × g for 30 min at 4°C. 
Cell lysates were added to blocking buffer (sonication buffer with 2.5% SDS and 20 mM 
MMTS) at 50°C for 20 min with frequent mixing using vortex. The proteins were precipitated 
with acetone at -20°C for 20 min, then the proteins were resuspended in blocking buffer (with 
1% SDS) following addition of 4 mM biotin-HPDP. After incubation for 3 hours at 25°C, 
biotinylated proteins were precipitated by streptavidin-agarose beads, which were then washed 
with blocking buffer. The biotinylated proteins were eluted by SDS-PAGE gel and subjected to 
Western blotting analysis using anti- LXRα antibody.  
 
2.11. Statistical Analysis  
 The data were presented as means ± SEM, representing at least 3 independent 
experiments. Statistical comparisons were made using two-tailed Student's t-tests or one-way 
ANOVA followed by a post-hoc analysis (Tukey test) where applicable. Values of p<0.05 were 
considered to be statistically significant.  
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3. Results 
3.1 The effects of doxorubicin and H2S treatment on HepG2 cell survival 
First, the effect of doxorubicin on HepG2 cell viability was evaluated with an MTT 
assay. We observed that cell viability was decreased in a dose-dependent manner when the cells 
were exposed to increasing concentrations of doxorubicin for 24 hours (Fig. 4A). Doxorubicin at 
1 µM decreased cell viability by 35.2%, while cell viability was only 28.2% in 10 µM 
doxorubicin-incubated cells in comparison with the control cells (100%). We next incubated 
HepG2 cells with NaHS, a well-known H2S-releasing donor (79). The result demonstrated that 
cell viability was not affected by exogenously applied NaHS (1-100 µM) (Fig. 4B). To further 
study the interaction of doxorubicin and H2S on cell viability, HepG2 cells were co-cultured with 
varying concentration of doxorubicin (0.1-10 M) and NaHS (30 M) for 24 hours.  The growth 
inhibitory effects of doxorubicin/NaHS combination were significantly higher than those caused 
by doxorubicin alone (Fig. 4C).  The cell viability in the treatment with both doxorubicin (1 M) 
and NaHS (30 M) was only 38.5% when compared with that (62.8%, p<0.05) in the treatment 
with doxorubicin (1 M) alone. As shown in Fig. 4D, doxorubicin at 1 M treatment 
significantly reduced HepG2 cell confluence, which was exaggerated by co-treatment with 30 
M NaHS over 24 hours. 
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Figure 4. H2S sensitizes HepG2 cells to doxorubicin cytotoxicity. (A) Doxorubicin dose-
dependently decreased cell viability. HepG2 cells were incubated with doxorubicin at the 
indicated concentration (0.03-10 µM) for 24 hours. After that, cell viability was measured by 
MTT assay. #, p<0.05 versus control. (B) NaHS had no effect on cell viability. HepG2 cells were 
incubated with NaHS (1-100 µM) for 24 hours. After that, cell viability was measured by MTT 
assay. (C) NaHS enhanced the sensitivity of HepG2 cells to doxorubicin cytotoxicity. HepG2 
cells were co-cultured with varying concentration of doxorubicin (0.1-10 M) and NaHS (30 
M) for 24 hours.  After that, cell viability was detected by MTT assay. *, p<0.05 versus the 
group with doxorubicin alone. (D) Morphology and confluence changes in HepG2 cells after 
treated with doxorubicin (1 M) and/or NaHS (30 M) for 24 hours. Scale bar: 20 m. The data 
were from at least 3 independent experiments.  
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3.2 H2S and doxorubicin-induced changes in the clonogenic formation of HepG2 cells 
An important hallmark of cancerous cells is the ability to quickly form large colonies, 
ultimately resulting in a tumorous mass. A clonogenic assay was then performed to quantify the 
effects of H2S and doxorubicin on the colony forming ability of HepG2 cells (73). HepG2 cells 
were treated 1 M doxorubicin and/or 30 M NaHS for 24 hours. The treated cells were then 
split to new plates at equal cell numbers and cultured for 2 weeks. The resultant colonies were 
visualized using crystal violet and quantified using image J software (Fig 5A). Co-treatment with 
both doxorubicin and H2S significantly inhibited colony formation to a greater degree than 
doxorubicin treatment alone, while NaHS treatment did not have a statistically significant effect 
(Fig 5B). 
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Figure 5. H2S sensitizes HepG2 cells to colony disruption by doxorubicin treatment. 
Following 24-hour treatments with 1 µM doxorubicin and/or 30 µM NaHS for 24 hours, the cells 
were split into fresh plates and re-cultured for 2 weeks. Colony formation was visualized using 
crystal violet staining (A) and number of colonies were quantified using image J software 
analysis (B). *, p<0.05 versus control; #, p<0.05 versus doxorubicin alone. The data were from 3 
independent experiments.  
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3.3 The effects of doxorubicin on H2S-generating enzymes in HepG2 cells 
  We next determined the effect of doxorubicin on the protein expressions of 3 H2S-
generating enzymes.  As observed in Fig. 6A, CSE protein expression was significantly 
decreased when HepG2 cells were treated with 1 M doxorubicin for 24 hours, while CBS 
expression was not affected by doxorubicin. The protein expression of 3MST was not detectable 
in HepG2 cells.  CSE is a major H2S-generating enzyme in liver tissues (14). We then measured 
the effect of doxorubicin on endogenous H2S generation from mouse liver tissues with a methyl 
blue method. Fig. 6B showed that doxorubicin significantly decreased H2S production by 80%, 
indicating that doxorubicin may also directly block CSE enzymatic activity. To further 
investigate the possibility of direct interaction between doxorubicin and H2S, doxorubicin at 1 
M was mixed with 30 uM NaHS, which was then exposed to lead acetate paper at 37°C for 1 
hour. As shown in Fig. 6C, it seems that there was no direct chemical reaction between 
doxorubicin and H2S.  
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Figure 6. Doxorubicin attenuates H2S production in HepG2 cells. (A) Doxorubicin inhibited 
the protein expression of CSE but not CBS. After HepG2 cells were treated with 1 M 
doxorubicin for 24 hours, the protein expressions were detected by western blotting. *, p<0.05 
versus control. (B) Doxorubicin reduced endogenous H2S production. Mouse liver tissues were 
processed for H2S measurement by methyl blue method in the presence of 1 M doxorubicin. *, 
p<0.05. (C) Doxorubicin did not react with H2S. Doxorubicin (1 M) and NaHS (30 µM) were 
mixed together followed by detection of H2S release by acetate lead paper at 37°C for 1 hour. *, 
p<0.05. The data were from at least four independent experiments. 
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3.4. H2S modulates doxorubicin trafficking in HepG2 cells 
To understand the mechanism underlying the synergistic effect of doxorubicin and H2S 
combination treatment, the efflux and influx of doxorubicin in HepG2 cells were measured with 
a fluorescence plate reader. We found that exogenously applied H2S inhibited the efflux of 
doxorubicin by 80% in comparison with doxorubicin treatment alone (Fig. 7A). As expected, 
intracellular doxorubicin concentration was increased significantly upon doxorubicin and NaHS 
combination treatment compared to that observed with doxorubicin alone (Fig. 7B). The 
differences of fluorescence intensity between doxorubicin alone and doxorubicin/H2S co-
treatment were further validated with a fluorescent microscopy (Fig 7C) 
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Figure 7. H2S promotes cellular retention of doxorubicin in HepG2 cells. H2S inhibited 
efflux of doxorubicin (A) but enhanced cellular retention of doxorubicin (B). Twenty-four hours 
after HepG2 cells were treated with doxorubicin and/or NaHS, the cells were washed and 
incubated with 2 mL PBS for additional 2 hours. Afterward, 1 mL sample of PBS was first taken 
for measurement of doxorubicin efflux (A). The cells were then collected for analysis of 
doxorubicin influx (B). Fluorescence intensity was normalized to equal amount of proteins 
loaded, and the intensity in doxorubicin treated group was expressed as 100%.  *, p<0.05.  The 
images of cellular doxorubicin internalization were captured using fluorescence inverted 
microscopy (C). Scale bar: 20 m. The data were from at least three independent experiments. 
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3.5 Effects of doxorubicin and H2S on the expression of ABC transport proteins in HepG2 
cells. 
 ABC transport proteins are responsible for the efflux of doxorubicin in many cell types 
(59). We next assessed the effect of both doxorubicin and H2S on the protein expression of 
several ABC transporters, including ABCA1, ABCB1 and ABCG8, which have been 
demonstrated to be highly expressed in HCC. In comparison with the control cells, incubation of 
HepG2 cells with 1 M doxorubicin for 24 hours increased the protein expressions of ABCA1 
and ABCG8 by 2.1 fold and 1.8 fold respectively (Fig. 8). The stimulatory effect of doxorubicin 
on ABCA1 and ABCG8 expressions was markedly reversed by exogenously applied H2S. In 
contrast, the protein expression of ABCB1 was not affected by either doxorubicin or H2S. These 
results suggest that the inhibition of ABCA1 and ABCG8 by H2S resulting in the increased 
accumulation of intracellular doxorubicin, is a potential mechanism underlying the synergistic 
effects of doxorubicin and H2S on cancer cell death. 
 
Figure 8. H2S reverses doxorubicin-induced expression of ABCA1 and ABCG8 but not 
ABCB1. HepG2 cells were treated with doxorubicin alone (1 M) and/or NaHS (30 M) for 24 
hours. The protein expressions of ABCA1, ABCG8, and ABCB1 were analyzed with western 
blotting. *, p<0.05 versus all other groups. The data were from four independent experiments. 
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3.6 The effect of doxorubicin and H2S on LXR expression and S-sulfhydration  
We further investigated the signalling pathways associated with altered expression of 
ABCA1 and ABCG8 by doxorubicin and H2S. The LXR group is a family of transcriptional 
regulatory proteins that have been associated with the regulation of ABC gene expression (60). 
Western blotting was further conducted to analyze the expressions of both LXR and LXR in 
HepG2 cells.  No change in the expression of LXR was seen with doxorubicin and/or H2S 
treatment (Fig. 9), while LXR was not detectable in this cell type. We then asked whether H2S 
can post-translationally modify LXR via S-sulfhydration leading to altered trans-activation 
activity. With a biotin switch assay, we did not detect LXR S-sulfhydration after the cells were 
treated with doxorubicin (1 M) and/or H2S (30 M) for 24 hours (data not shown).  These data 
exclude the possibility of LXR/ in mediating the altered expressions of ABCA1 and ABCG8 
by doxorubicin and H2S. 
 
Figure 9.  LXR is not altered by doxorubicin and/or H2S.  HepG2 cells were treated for 24 
hours with doxorubicin (1 M) and/or NaHS (30 M). The protein expressions of LXR and 
LXR were then analyzed by western blotting. The experiments were repeated for 3 times. 
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3.7 Doxorubicin and H2S regulate GST and SLC22A1 expression in HepG2 cells  
To further explore other mechanisms for the increased retention of doxorubicin by H2S, 
the mRNA expression level of GST and SLC22A1 were determined by real-time PCR. GST is 
capable of detoxifying doxorubicin through catalyzing it’s conjugation with glutathione (62), 
while SLC22A1 has been proposed as a potential doxorubicin influx transport protein (67). 
Doxorubicin slightly induced the mRNA expression of GST, but it did not reach significance. In 
addition, NaHS alone or doxorubicin and NaHS combination significantly induced GST mRNA 
expression (Fig. 10). More interestingly, doxorubicin and NaHS combination treatment 
stimulated the mRNA expression of SLC22A1 by 160% when compared with the control cells. 
Either doxorubicin or NaHS alone had no significant effect on SLC22A1 expression. 
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Figure 10. Effect of doxorubicin and H2S on the mRNA expression of GST and SLC22A1. 
HepG2 cells were treated for 24 hours with doxorubicin (1 M) and/or NaHS (30 M). The cells 
were then collected for real-time PCR analysis of GST and SLC22A1 mRNA expressions.  *, 
p<0.05 versus control. The data were from four independent experiments. 
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3.8. Characterization of doxorubicin drug resistance in HepG2 cells 
To further elucidate the functional significance of H2S in drug resistance in HCC, we 
established an in vitro model of doxorubicin-resistant HepG2 cells (D.R. HepG2) by long term 
treatment of HepG2 cells with low dose of doxorubicin (80). In comparison with the parental 
(W.T.) HepG2 cells, D.R.-HepG2 cells were flatter with an enlarged cytoplasm (Fig. 11A). We 
further observed that CSE expression was quite lower in D.R. HepG2 in comparison with the 
W.T. HepG2 cells (Fig. 11B). Next, we compared the sensitivity of both cell types to 
doxorubicin and H2S. After seeding equal numbers of both cell types in new plates, D.R. HepG2 
grew faster (122%) than the parental W.T. HepG2 cells (100%) in the normal culture medium. 
Doxorubicin at 1 μM decreased HepG2 cell viability by 61.5% but only 12.3% in D.R. HepG2 
cells, suggesting that D.R. HepG2 cells are resistant to doxorubicin-arrested cell growth. NaHS 
at 30 μM had no effect on the cell viability of parental W.T. HepG2 cells but significantly 
decreased the viability of D.R. HepG2 cells. The addition of NaHS restored the sensitivity of 
D.R. HepG2 cells to doxorubicin-induced cell growth inhibition (Fig. 11C).  
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Figure 11. H2S sensitizes drug resistant D.R. HepG2 cells to doxorubicin treatment. (A) 
D.R. HepG2 cells were flatter with an enlarged cytoplasm.  D.R. HepG2 cells were obtained by 
continuous exposure to low dose doxorubicin (50-75 nM) for a period of over 2 months. (B) CSE 
expression was lower in D.R. HepG2 cells. Both parental W.T. HepG2 cells and W.T. HepG2 
cells were cultured in normal medium without doxorubicin for 1 week prior to detection of CSE 
expression by western blotting. (C) H2S sensitized D.R. HepG2 cells to doxorubicin treatment. 
Equal number of parental W.T. HepG2 cells and D.R. HepG2 cells were seeded in 96-well plate 
for 1 days followed by treatment with doxorubicin (1 µM) and/or NaHS (30 µM) for 24 hours. 
After that, cell viability was analyzed by MTT assay. *, p<0.05 versus parental W.T.  control; #, 
p<0.05 versus parental W.T. cells with doxorubicin treatment; &, p<0.05 versus D.R. HepG2 
cells with no treatment or doxorubicin treatment. The experiments were repeated for at least 3 
times. 
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4. Discussion 
 One of the major limitations in the chemotherapeutic treatment of cancer is the 
development of MDR. In HCC, MDR is characterized by changes in drug transport, metabolism, 
and its ability to alter intracellular targets. Given the unique and critical role of H2S in various 
cellular functions, the ability of H2S to regulate the development of MDR in HCC deserves 
further investigation (81).  
 
 The chemotherapeutic agent doxorubicin has been well described as having strong anti-
proliferative effects in cancer lines including HepG2. Doxorubicin induces cell death through the 
direct intercalation with DNA and disruption of topoisomerase II, as well as through the 
production of ROS. ROS themselves can induce oxidative damage to cellular membranes, DNA, 
and proteins, due to the reactivity of the oxygen free radicals (82).  Our studies here validated 
that doxorubicin reduces HepG2 cell viability in a dose-dependent manner, and H2S 
supplementation (30 M) sensitizes the cells to doxorubicin cytotoxicity, while H2S treatment 
alone has no effect on cell viability. These results were further confirmed by the studies with 
colony formation. Consistent with the cell viability data, exogenously applied H2S strengthens 
the ability of doxorubicin to disrupt HepG2 colony formation, while H2S alone has no effect on 
colony formation. A 30 M NaHS treatment was selected because, upon dissociation, this 
chemical would supply an H2S dosage in the low M range, most closely reflecting endogenous 
H2S production levels (14). Also, the rapid release of H2S from NaHS treatments allowed for 
effective co-treatment timing with doxorubicin (79).  
 
  41
          To further investigate the mechanism associated with these changes in doxorubicin 
cytotoxicity, the expression of a group of membrane-bound efflux transport proteins known as 
the ABC transport proteins was studied. Of the members of the ABC group, ABCB1 is the most 
well described in MDR development for its ability to facilitate the efflux of chemotherapeutic 
agents including doxorubicin, and thus reduce their cytotoxicity (83). ABCA1 and ABCG8 were 
also selected for analysis because of their high levels of expression in the liver, their role in 
hepatic efflux transport, as well as the lack of research investigating their role in MDR 
development (51, 84). Current understanding on the role of ABCA1 focuses on it’s importance 
as a cholesterol efflux transporter expressed highly in the liver (84), however some evidence has 
shown an ability for it to regulate chemotherapeutic cytotoxicity in lung cancer cells (58). 
Likewise, there has been little insight on the role of ABCG8 in MDR development, however 
ABCG2/BCRP, a member of the same sub-group, has been well described as an MDR protein in 
breast cancer cells (57). We have shown that in doxorubicin (1 M) treated HepG2 cells, the 
expression of both ABCA1 and ABCG8 is increased, and that H2S supplementation (30 M) 
returns the expression level of these proteins back to a control state, while the expression of 
ABCB1 was shown to not be affected by any of the treatments. H2S treatment (30 M) alone did 
not affect the expression of any of the proteins. Overexpression of ABC transport proteins is one 
of the most well described mechanisms for the onset of MDR, as the increased number of efflux 
transporters reduces the ability for chemotherapeutics to accumulate in the cancerous cells and 
carry out their cytotoxic functions (85). The ability for H2S treatments to restrict the expression 
of these proteins could explain the increase in doxorubicin/H2S co-treatment cytotoxicity seen in 
the cell viability studies. To determine if doxorubicin/H2S-induced changes in ABCA1 and 
ABCG8 levels correspond to changes in doxorubicin transport, a doxorubicin fluorescence assay 
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was performed in HepG2 cells. Using doxorubicin’s intrinsic fluorescent qualities, the 
intra/extracellular localization of doxorubicin could be tracked (76) . These results show that co-
treatment of doxorubicin (1 M) with H2S (30 M) increases the intracellular fluorescence, and 
therefore doxorubicin content, of HepG2 cells. Some studies have suggested that intracellular 
doxorubicin fluorescence may not be reflective of intracellular toxicity, as inactivated 
doxorubicin can still fluoresce (86). However, the doxorubicin/H2S cell viability studies can 
confirm that an H2S-induced increase in doxorubicin accumulation causes increased cytotoxicity 
and thus HepG2 cell death. Our findings therefore suggest an expanded role for ABCA1 and 
ABCG8 in HCC cells, as efflux transporters of chemotherapeutic agents, specifically 
doxorubicin. The importance of ABCB1 in MDR has been well established in several different 
cancer lines including HepG2, however, our results suggested otherwise (87, 88). It is important 
to note that previous studies have conducted their experiments with established doxorubicin 
resistant cell lines, without studying the effects of initial doxorubicin treatment in wild-type 
cells. As such, their results may reflect the exaggerated changes in ABC transport protein 
expression seen in already resistant cell lines. Our findings may instead reflect more sensitive 
changes seen in the initial establishment of doxorubicin resistance in wild-type cells, offering 
novel insight into the importance of other ABC transporters previously not studied.  
 
 The Liver X Receptor (LXR) group is a family of nuclear receptors that are important 
regulators of cholesterol metabolism. The two subgroups, LXR and LXR, differ only in tissue 
distribution, with LXR predominately in the liver, and LXR found in most tissues. The 
importance of both LXR groups in the regulation of cholesterol metabolism makes them key 
regulators of certain ABC-transport protein expression (89). In one study, it was shown that the 
  43
hepatic expression of ABCG8 and ABCA1 is greatly reduced by the inhibition of LXR and  
(60). In a separate study, the use of LXR agonists had no effect on the regulation of ABCB1 in 
HepG2 cells (90). Taken together, these findings suggest that H2S is capable of regulating 
specifically ABCA1 and ABCG8, but not ABCB1, through the targeting of LXR’s in HepG2 
cells. In order to study this, HepG2 cells were treated with doxorubicin (1 M) with or without 
NaHS (30 M) and NaHS (30 M alone). We found no effect of any treatment group on the 
expression of LXR, while LXR was not expressed at measurable levels. Given these results, it 
is unlikely that H2S modulates the expression of LXR to exert its regulatory effects over 
ABCA1 and ABCG8. We next wanted to investigate the ability of H2S to instead regulate the 
activity of LXR through protein S-sulfhydration. Through the addition of sulfur groups to the 
cysteine residues of target proteins, H2S is capable of inducing changes in the structure and thus 
the function of proteins (5). Again, it was shown that H2S treatment had no measurable effect on 
the level of LXR sulfhydration, allowing us to conclude that the LXR group is unlikely the 
intermediate signaling complex through which H2S exerts its effects on ABCA1 and ABCG8. 
Our future studies will look to investigate other possible regulatory elements through which H2S 
regulates ABC protein expression. One possible candidate for this role is the retinoid X receptor 
(RXR) group, a family of nuclear receptors expressed highly in the liver and associated with 
regulation of cholesterol metabolism through the formation of heterodimers with LXR/ (91). 
Studies have shown the ability for RXR activation to induce the expression of ABCA and ABCG 
subgroup members, pointing to the possibility of RXR as the intermediate signaling complex 
between H2S and ABCA1/G8 (92). 
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 While efflux transport is the best described mechanism associated with MDR, the 
pathways associated with influx transport and metabolism may offer new research avenues for 
the prevention of this condition in HCC. The role of the SLC transporter group of proteins is just 
now becoming recognized for its potential role in the influx transport of various 
chemotherapeutics, including doxorubicin (93). The SLC group is responsible for regulating 
metabolite and ion influx but has also shown the ability to regulate chemotherapeutic influx as 
well, specifically in the SLC22 subfamily. SLC22A1-transfected colon cancer cells showed a 
significant increase in the accumulation of oxaliplatin, a derivative of cisplatin, improving the 
cytotoxicity of the drug. Further studies showed differential mRNA expression of SLC22A1in 
various colon cancer tumors, suggesting tissue specific variations in the degree of 
chemotherapeutic effectiveness (94). In order to describe the role of SLC22A1 in the regulation 
of doxorubicin management in HepG2 cells, we treated the cells with doxorubicin (1 M) with 
or without NaHS (30 M) and NaHS (30 M alone) (Fig 10). The findings showed that 
doxorubicin treatment alone had no effect on the levels of SLC22A1 mRNA in Hep-G2 cells, 
and thus is unlikely to be associated with the onset of MDR in this cell line. Co-treatment with 
both doxorubicin and H2S showed an increase in SLC22A1 mRNA expression, however H2S 
treatment alone had no significant effect. Both doxorubicin alone and H2S alone treatments 
showed an increasing trend, and despite not being enough to qualify for statistical significance, 
could describe the synergistic effect that combined treatment had. As such, it is plausible that 
both doxorubicin and H2S treatment function to improve doxorubicin intracellular accumulation, 
however in a pathway distinct from that regulating ABC transport proteins. The likelihood for 
distinct regulatory mechanisms controlling both chemotherapeutic influx and efflux offers both 
daunting and exciting research possibilities. 
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 The metabolism of chemotherapeutic agents is another mechanism in which drug 
resistance can be established. The GST family is a large group of enzymes capable of processing 
toxic chemical agents for removal from the body. Elevated levels of GST across various cell 
lines has been associated with the development of MDR, and thus may be associated with similar 
regulation in HepG2 cells (95, 96). In the present study, doxorubicin treatment alone had no 
effect on the levels of GST expression, however we saw an increasing trend, suggesting that 
longer, or higher dose treatments perhaps could exaggerate these effects. Combined treatment of 
doxorubicin and NaHS showed a significant increase in GST mRNA, indicating a synergistic 
effect similar to that seen in the regulation of SLC22A1. H2S alone also significantly increased 
GST expression in these cells. These findings taken alone may indicate that H2S actually 
perpetuates MDR through the up regulation of GST, but given our cell viability findings and the 
cellular level effects of H2S on doxorubicin toxicity, this is unlikely to be the case. While studies 
have shown that H2S up regulates GST levels in various cell lines (97, 98), our cell viability and 
clonogenic studies suggest that the sum of the effects of H2S on doxorubicin cytotoxicity in 
HepG2 cells is an increased sensitivity to the drug.  
 
 We also tested the effect of doxorubicin on endogenous H2S signaling in HepG2 cells. 
The protein levels of all 3 of the H2S-generatng enzymes, including CSE, CBS and 3-MST, were 
compared following doxorubicin treatment (1 M). Our findings demonstrated that only CSE but 
not CBS was down-regulated by doxorubicin. The protein expression of 3-MST was not 
detected. It has been observed that CSE is highly expressed in liver tissues, and knockout of CSE 
diminishes most H2S production in mouse liver tissues, supporting our findings (14). We also 
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measured the effect of doxorubicin on H2S production rate in mouse liver tissues and found that 
doxorubicin significantly reduced the production rate of H2S in these tissues.  These same effects 
were also reported in rat cardiac (H9C2) cells (99) following 24 hour doxorubicin (5 M) 
treatment. Together, these findings strongly suggest that doxorubicin is capable of inhibiting 
CSE expression, and therefore endogenous H2S production in HepG2 cells, possibly through its 
strong DNA intercalation properties, however this requires further investigation (100). When 
considered with the data of cell viability, doxorubicin transport, and ABC protein expression 
data, it seems that this loss of H2S production ultimately leads to pro-MDR related signaling 
events in HepG2 cells.   
 
 We have also established a doxorubicin resistant (75 nM) HepG2 cell line in order to 
study changes in H2S signaling and doxorubicin sensitivity, and to compare these characteristics 
with wild-type HepG2 cells. Morphological features of the D.R. cell line included an irregular 
shape and enlarged cytoplasm, characteristics similar to those of doxorubicin resistant breast 
cancer cells (101). Some studies have focused on the importance of epithelial-mesenchymal 
transition (EMT) in the morphological changes associated with MDR cells. EMT is a process in 
which cancerous cells undergo cytoskeletal rearrangement to improve their migratory ability 
(102). In various cancer cell lines, increased activity of the EMT pathway has been associated 
with not only metastasis, but also the onset of MDR. Resistant cells often exhibit EMT 
phenotype changes including increases in cell size and irregular cell structure (103). The role of 
EMT in HepG2 MDR development has yet to be studied but could present an important avenue 
of future research. Upon establishment of a D.R. HepG2 cell line, experiments were performed 
to determine changes in doxorubicin sensitivity and H2S production between W.T. and D.R. cell 
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lines.  Non-treated D.R. HepG2 cells exhibited a significant decrease in CSE expression 
compared to W.T. cells, similar to that seen in doxorubicin treated W.T. cells. The ability for 
D.R. alone to induce CSE down-regulation without direct doxorubicin treatment suggests that it 
may not be the doxorubicin itself effecting CSE expression, but instead doing so through an 
indirect signaling mechanism, however this requires further investigation. Decreased H2S 
producing enzyme levels in D.R. but not W.T. cells, once again implicates the importance of 
endogenous H2S in regulating doxorubicin transport. In order to study the effects of D.R. 
resistance on doxorubicin/H2S induced cell death, cell viability analysis was performed on both 
W.T. and D.R. Hep-G2 cells. The statistically significant decrease seen in the viability of 
doxorubicin treated W.T. cells, but not in the doxorubicin D.R. cells, confirmed doxorubicin 
treatment was no longer an effective inhibitor of cell growth, and thus further confirmed this 
group as a doxorubicin resistant cell line. When exogenous H2S was combined with doxorubicin 
treatment, both the W.T. and D.R. groups saw a very similar decrease in cell viability, greater 
than with doxorubicin alone. This further confirmed that H2S is capable of sensitizing HepG2 
cells to doxorubicin treatment, and in D.R. cells, actually returns their sensitivity back to a WT 
state. Applied in a clinical context, H2S therefore could be used in conjugation with doxorubicin 
to not only improve initial doxorubicin treatment, but also to restrict the onset of MDR in HCC 
tissues. Recent studies have investigated doxorubicin/H2S co-treatment in prostate and bone 
cancers and have even synthesized H2S-releasing doxorubicin compounds. These compounds 
have shown an increased ability both in-vitro and in-vivo to reduce tumor size and induce 
cellular apoptosis through supplementation of doxorubicin with simultaneous H2S release (104, 
105). 
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5. Conclusions and future studies  
 These findings have shown that doxorubicin treatment is capable of decreasing CSE 
expression in HepG2 cells, and that exogenous H2S is capable of sensitizing HepG2 cells to 
doxorubicin treatment, possibly by suppressing doxorubicin transporters, ABCA1 and ABCG8. 
These effects are not mediated by the interaction between H2S and LXR family members, but 
perhaps through other related signaling complexes such as the RXR group, since RXR’s regulate 
the transcription of ABC transporters by interaction with LXR.  In addition, we discovered that 
H2S is capable of returning the sensitivity of doxorubicin resistant Hep-G2 cells to a non-
resistant level. The ability for H2S to sensitize HepG2 cells to doxorubicin treatment offers the 
possibility for improving the management of HCC through the use of chemotherapeutic agents. 
H2S supplementation with doxorubicin may improve both the initial response of HCC treatment, 
as well as offer the ability to return D.R. HCC cells to a non-resistant state. The discovery of 
ABCA1 and ABCG8 as important transporters of doxorubicin in HepG2 cells, and the ability for 
H2S to regulate their expression improves not only our understanding of the mechanisms 
associated with MDR development, but also the role of H2S in liver physiology as whole. We 
hope that these novel regulatory functions of H2S in the liver will be the basis for improving 
current HCC treatment methods, and will contribute to the development of H2S as a clinically 
relevant tool. Building upon these findings, future studies will look to determine; A) how 
doxorubicin alters CSE expression in both W.T. and D.R. HepG2 cells; B) the mechanism in 
which H2S affects ABCA1 and ABCG8 expression if not through LXR/; C) exploring the role 
of doxorubicin/H2S on tumor growth in-vivo, through the use of xenograft animal models with 
W.T. vs D.R. induced HCC tumors; D) synthesizing novel H2S-releasing doxorubicin 
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compounds capable of effectively targeting HCC tissues to improve current HCC treatment tools 
and strategies. 
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